Whistle-blower: Walgreen saw "unique opportunity" to substitute more expensive meds

09/13/2011 | BNET

A whistle-blower lawsuit accuses Walgreen executives of encouraging pharmacists to switch patients' Zantac tablet prescriptions to a Par Pharmaceuticals capsule version that cost up to three times as much. Par representatives alerted Walgreen managers that Medicaid limited reimbursement for the tablet version but not for the capsule version. Walgreen's director of pharmacy marketing allegedly told pharmacists that substituting the easier-to-swallow capsules for the tablets was "a unique opportunity" to interact with patients.

View Full Article in:

BNET

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Executive Officer
UCare Minnesota
Minneapolis, MN